Regarding AML-free survival, there was also no significant difference between SRSF2-mutated and SRSF2-nonmutated patients in either cohort: median AML-free survival was 134 months vs. not reached (p = 0.348) in the ABCMML cohort and 25.2 vs. 30.0 months (p = 0.418), respectively, in the cBioPortal cohort. The gene discussed is SRSF2; the disease is acute myeloid leukemia.